A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma


To compare the efficacy of TACE with Duravalumab + Bevacizumab, TACE with Duravalumab alone and TACE only.


Age ≥18 years at the time of screening

Confirmed HCC based on histopathological findings from tumor tissue

No evidence of extrahepatic disease on baseline chest/abdomen/pelvis imaging

Disease not amenable to curative surgery or transplantation or curative ablation

Disease must be amenable to TACE

You Cannot

·         Have any clinically significant cardiovascular disease

·         Have a history of a stroke or myocardial infarction

·         Have had any kind of surgery in the past 28 days

·         Have uncontrolled hypertension

·         Have clinically meaningful ascites

·         Have a history of prior TACE, prior bland embolization, or prior radioembolization

·         Have received prior systemic anticancer therapy

·         Current or prior use of immunosuppressive medication within 14 days


This study will be conducted in patients with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation).  Study will enroll 600 patients globally.

                    Arm A: Durvalumab +TACE then Durvalumab + bevacizumab placebo (every 3weeks)

            Arm B: Durvalumab  + TACE then Durvalumab + bevacizumab 15 mg/kg (every 3weeks)

            Arm C: Durvalumab +TACE then Durvalumab placebo + bevacizumab placebo (every 3weeks)        


Interested in more information on clinical research? Contact WK Health System Clinical Research Department 318-212-8130 or ckay@wkhs.com

Interested in more information? Contact Us:

Hematology Oncology Associates

IRB Number:
Trial Type: NA
Sponsor: Astra Zenca